Novo Nordisk A/S
corporate_fare Company Profile
Novo Nordisk A/S (NYSE:NVO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for NVO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for NVO spans 6-K.
Recent high-impact activity:
- Novo Lifts 2026 Outlook as Q3 Sales and Profit Beat, Wegovy Pill Sets Launch Record
- Novo Raises 2026 Outlook as Q3 Adjusted Operating Profit Jumps 27% at CER
- Novo Lifts Full-Year Outlook as Wegovy Pill Demand Beats Expectations
- Judge Denies Novo Nordisk Bid to Halt Lilly's Weight-Loss Drug Ads
- FDA Extends Denecimig Review; US Launch Slips to H1 2027
Financial Snapshot
Short Interest & Short Volume
4.04 days to coverFINRA reported short interest of 38,286,865 shares in NVO as of the October 30, 2026 settlement, a 2.3% increase from the prior period — about 4.0 days to cover at its recent average daily volume. On November 19, 2026, 28.8% of NVO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
NVO files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.